ExpreS2ion Biotech Holding, a biopharmaceutical company based in Denmark, intends for a rights offering of 2,400,403 shares at a price of Skr8 ($0.99) each to raise Skr19.2m ($2.39m).
The company has received subscription commitments for Skr10.9m ($1.36m), representing 57% of the issue size, from persons and entities such as management, major shareholders and institutions.
The proceeds are intended to be used for working capital purpose and to implement projects related to vaccines and candidate drugs, as well as to create an additional value in the joint venture AdaptVac and its development projects. Part of the proceeds will also be used for developing new products.
Sedermera Fondkommission is the financial advisor for the transaction.
Canadian biopharmaceutical company Arbutus Biopharma has completed the final private placement of 664,000 series A participating convertible preferred shares at a value of $100 a share to raise $66.4m.
The latest transaction has increased Arbutus Biopharma’s total funds in the first and second tranches of private placements to $116.4m. The first tranche involved placement of 500,000 convertible preferred shares at a price of $100 a share to raise $50m in October 2017, which was subscribed to by Roivant Sciences.
The company was assisted by MTS Securities as financial adviser, and Farris, Vaughan, Wills & Murphy and Dorsey & Whitney as legal advisors.
Lawson Lundell and White & Case acted as the legal advisors for Roivant in the transaction.
Intrexon has completed an underwritten public offering of shares of its common stock.
The US-based therapeutic solutions provider plans to use the proceeds for general corporate purposes and for strategic acquisitions or investments.
JMP Securities was the book-running manager, while Hogan Lovells US was the legal advisor for the transaction.
China-based bio-pharmaceutical company Innovent Biologics plans to raise funds through an initial public offering (IPO) of shares.
The company simultaneously intends to raise funds through venture financing from Capital Group Cos and other investors.
BeiGene, a commercial-stage bio-pharmaceutical company based in China, intends for public offering of its American depository shares (ADS) to raise $650m.
Each ADS will represent 13 ordinary shares of the company.
Underwriters will be granted a 30-day option to purchase additional ADS worth $50m.
The proceeds are intended to be used for working capital and other general corporate purposes.
Lidds (Local Intelligent Drug Delivery System), a pharmaceutical company based in Sweden, plans for a private placement of 890,419 shares.
Priced at Skr715.12 ($1.87) a share, the transaction will raise a total of Skr13.46m ($1.67m).
The placement will be subscribed to by Nyenburgh Holding.
The proceeds will be used for accelerating the company’s development projects in immuno-oncology.